Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs will be updated on May 1, 2026 and will take effect on June 1, 2026:
Prescription Drug Policies
- Afrezza
- Aqvesme
- Constipation Agents
- Galafold
- Joenja
- Jynarque
- SA Oncology
- Substrate Reduction Therapy
- Tavneos
- Vijoice
- Weight Loss Agents
To view prescription drug policies specific to a formulary or medication list, please select that formulary on the Prior Authorization page of our website.
Medical Pharmacy Solutions Program Policies
- Aflibercept
- Bevacizumab_ONCO
- Cabazitaxel
- Cimzia
- Cinqair
- Cosentyx
- Darzalex_SQ
- Docetaxel
- Entyvio IV
- Exdensur
- Fasenra
- Gamifant
- Ilumya
- Infliximab
- Keytruda_IV
- Keytruda_SQ
- Leqvio
- Lymphir
- Nucala
- Omvoh
- Orencia
- Paclitaxel Albumin-Bound
- Provenge
- Rybrevant Faspro
- Simponi_ARIA
- Skyrizi IV
- Tezspire
- Tocilizumab_IV
- Trastuzumab_IV
- Tremfya
- Ustekinumab
- Xolair
- Yescarta
To access Medical Pharmacy Solutions policies, please visit the Medical Pharmacy Policies (GatewayPA) page.
For additional questions, please refer to the Prior Authorization section of our website or contact your BCBSKS provider relations representative.